Geode Capital Management LLC Has $28.46 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Geode Capital Management LLC lessened its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 5.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,271,207 shares of the biopharmaceutical company’s stock after selling 180,880 shares during the period. Geode Capital Management LLC owned 2.10% of Ocular Therapeutix worth $28,464,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Bank of New York Mellon Corp grew its holdings in shares of Ocular Therapeutix by 49.6% during the second quarter. Bank of New York Mellon Corp now owns 495,635 shares of the biopharmaceutical company’s stock worth $3,390,000 after purchasing an additional 164,383 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Ocular Therapeutix by 757.9% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,044 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 28,309 shares during the period. Atlas Capital Advisors LLC bought a new stake in Ocular Therapeutix during the 2nd quarter worth approximately $34,000. Aptus Capital Advisors LLC acquired a new position in Ocular Therapeutix in the 2nd quarter valued at approximately $1,798,000. Finally, Rhumbline Advisers raised its stake in shares of Ocular Therapeutix by 39.1% during the second quarter. Rhumbline Advisers now owns 211,301 shares of the biopharmaceutical company’s stock valued at $1,445,000 after acquiring an additional 59,345 shares during the last quarter. Institutional investors and hedge funds own 59.21% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on OCUL. Scotiabank started coverage on shares of Ocular Therapeutix in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $22.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, December 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Ocular Therapeutix presently has an average rating of “Moderate Buy” and an average price target of $16.71.

Ocular Therapeutix Stock Up 2.5 %

Shares of NASDAQ:OCUL opened at $8.54 on Friday. Ocular Therapeutix, Inc. has a 1 year low of $3.76 and a 1 year high of $11.77. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The business’s 50-day moving average is $9.84 and its 200-day moving average is $8.67. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of -6.47 and a beta of 1.20.

Insiders Place Their Bets

In related news, insider Jeffrey S. Heier sold 2,948 shares of the stock in a transaction on Monday, November 25th. The shares were sold at an average price of $9.01, for a total transaction of $26,561.48. Following the transaction, the insider now directly owns 269,059 shares of the company’s stock, valued at $2,424,221.59. This represents a 1.08 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.50% of the stock is currently owned by corporate insiders.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.